Post Test: Non-Small Cell Lung Cancer: Clinical and Economic Considerations in Targeting Therapy Based on Molecular Profiling

Published Online: January 01, 2014
Instructions

After reading “Non-Small Cell Lung Cancer: Clinical and Economic Considerations in Targeting Therapy Based on Molecular Profiling,” complete the program evaluation and select the single best answer to each of the posttest questions.

A statement of continuing education credit will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher on the posttest.




Take Physician CME Test

Take Pharmacist CE Test



PDF
Feature
Recommended Articles
Although the cost of oral oncolytic medications can vary greatly, cost sharing routinely plays less of a role because patients with cancer nearly always reach their maximum out-of-pocket limits, especially in late-stage disease care. Bruce A. Feinberg, DO, and Brian B. Kiss, MD, recently addressed this issue in the final segment on palliative care from the Oncology Stakeholders Summit, Spring 2015 meeting.
In the sixth entry of our Insights discussion on palliative care from the Oncology Stakeholders Summit, Spring 2015 meeting, Bruce A. Feinberg, DO, and Brian B. Kiss, MD, address the decision-making process regarding whether a patient receives oral or infusion medications during end-of-life care.
Patient-reported outcomes are beginning to influence FDA approvals and coverage decision making by payers. How oral oncolytics are affecting quality of life and patient preferences was also discussed in this fifth segment of the Oncology Stakeholders Summit, Spring 2015 series, with Bruce A. Feinberg, DO, and Brian B. Kiss, MD.
Although GOP presidential hopefuls are all campaigning on promises to repeal and replace President Obama's Affordable Care Act (ACA), the last real chance to repeal may have been the 2012 election, according to Avik Roy, senior fellow at the Manhattan Institute.